PROTIA INC. Logo

PROTIA INC.

Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.

303360 | KO

Overview

Corporate Details

ISIN(s):
KR7303360002
LEI:
Country:
South Korea
Address:
서울특별시 강서구 양천로 401, 강서한강자이타워 A동 702호, 강서구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PROTIA INC. is an in vitro diagnostics (IVD) company that designs, develops, and manufactures a wide range of diagnostic kits and instruments. Leveraging patented technologies and proteomics-based biomarker research, the company offers solutions across multiple medical fields, including allergy, point-of-care testing (POCT), infectious diseases, autoimmune disorders, cancer, and animal diagnostics. PROTIA is particularly recognized for its high-performance multiplex allergy diagnostic kits, such as the PROTIA Allergy-Q series. The company also developed the world's first total IgG quantitative POCT kit using whole blood. In addition to its products, PROTIA provides specialized protein analysis and custom research services, including protein identification, characterization, and rapid kit development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-12 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-07-22 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-07-18 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.5 KB
2025-05-09 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-04-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 20.4 KB
2025-03-18 00:00
Audit Report / Information
감사보고서제출
Korean 18.4 KB
2025-03-18 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.3 MB
2025-03-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 170.9 KB
2025-02-24 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 10.9 KB
2025-01-24 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.0 KB
2025-01-09 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.4 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 188.1 KB

Automate Your Workflow. Get a real-time feed of all PROTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PROTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PROTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.